Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Available at: This article is intended for research and educational purposes
The GetGoal programme established the efficacy and safety profile of lixisenatide 20 g once daily across the spectrum of patients with type 2 diabetes, including patients not treated with anti-diabetic agents, those failing on oral agents and as an adjunct to basal insulin therapy
The full arc is in the pillar update
OMN9 is on a mission to drive innovation and consumer awareness on all things protein
Vestergaard P
10.1016/j.tibs.2014.02.002 Trends Biochem
US$ 29.01
US$ 23.92
US$ 27.26
US$ 29.37
